Literature DB >> 30815685

Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.

Ilona Baraniak1, Florian Kern2, Pavlo Holenya3, Paul Griffiths1, Matthew Reeves1.   

Abstract

A human cytomegalovirus (HCMV) vaccine is urgently needed to protect against primary infection and enhance existing immunity in HCMV-infected individuals (HCMV+). Using sera from HCMV+ glycoprotein B/MF59 vaccine recipients prior to transplant, we investigated the composition of the immune response. Vaccination boosted preexisting humoral responses in our HCMV+ cohort but did not promote de novo responses against novel linear epitopes. This suggests that prior natural infection has a profound effect on shaping the antibody repertoire and subsequent response to vaccination ("original antigenic sin"). Thus, vaccination of HCMV+ may require strategies of epitope presentation distinct from those intended to prevent primary infection.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibody responses; cytomegalovirus; original antigenic sin; vaccination

Mesh:

Substances:

Year:  2019        PMID: 30815685      PMCID: PMC6581893          DOI: 10.1093/infdis/jiz089

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization.

Authors:  Andrea Speckner; Diana Glykofrydes; Mats Ohlin; Michael Mach
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

2.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.

Authors:  David I Bernstein; Flor M Munoz; S Todd Callahan; Richard Rupp; Susan H Wootton; Kathryn M Edwards; Christine B Turley; Lawrence R Stanberry; Shital M Patel; Monica M Mcneal; Sylvie Pichon; Cyrille Amegashie; Abbie R Bellamy
Journal:  Vaccine       Date:  2015-12-02       Impact factor: 3.641

Review 4.  Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Authors:  Robert F Pass
Journal:  J Clin Virol       Date:  2009-07-31       Impact factor: 3.168

Review 5.  Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.

Authors:  Ilona Anna Baraniak; Matthew B Reeves; Paul D Griffiths
Journal:  Rev Med Virol       Date:  2017-11-17       Impact factor: 6.989

6.  Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

Authors:  Ilona Baraniak; Barbara Kropff; Lyn Ambrose; Megan McIntosh; Gary R McLean; Sylvie Pichon; Claire Atkinson; Richard S B Milne; Michael Mach; Paul D Griffiths; Matthew B Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

7.  Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy.

Authors:  S F Atabani; C Smith; C Atkinson; R W Aldridge; M Rodriguez-Perálvarez; N Rolando; M Harber; G Jones; A O'Riordan; A K Burroughs; D Thorburn; J O'Beirne; R S B Milne; V C Emery; P D Griffiths
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

Review 8.  The Doctrine of Original Antigenic Sin: Separating Good From Evil.

Authors:  Arnold S Monto; Ryan E Malosh; Joshua G Petrie; Emily T Martin
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

9.  Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.

Authors:  Ilona Baraniak; Barbara Kropff; Gary R McLean; Sylvie Pichon; Fabienne Piras-Douce; Richard S B Milne; Colette Smith; Michael Mach; Paul D Griffiths; Matthew B Reeves
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

Review 10.  The pathogenesis of human cytomegalovirus.

Authors:  Paul Griffiths; Ilona Baraniak; Matt Reeves
Journal:  J Pathol       Date:  2015-01       Impact factor: 7.996

View more
  5 in total

1.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.

Authors:  Pavlo Holenya; Paul Joris Lange; Ulf Reimer; Wolfram Woltersdorf; Thomas Panterodt; Michael Glas; Mark Wasner; Maren Eckey; Michael Drosch; Jörg-Michael Hollidt; Michael Naumann; Florian Kern; Holger Wenschuh; Robert Lange; Karsten Schnatbaum; Frank F Bier
Journal:  Eur J Immunol       Date:  2021-05-07       Impact factor: 5.532

Review 3.  The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.

Authors:  Ariane C Gomes; Paul D Griffiths; Matthew B Reeves
Journal:  Vaccines (Basel)       Date:  2019-07-17

4.  Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults.

Authors:  Flavia Camponovo; Joseph J Campo; Timothy Q Le; Amit Oberai; Christopher Hung; Jozelyn V Pablo; Andy A Teng; Xiaowu Liang; B Kim Lee Sim; Said Jongo; Salim Abdulla; Marcel Tanner; Stephen L Hoffman; Claudia Daubenberger; Melissa A Penny
Journal:  Elife       Date:  2020-07-14       Impact factor: 8.140

Review 5.  Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.

Authors:  Michela Perotti; Laurent Perez
Journal:  Viruses       Date:  2019-12-28       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.